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of tranexamic acid: an exploratory analysis
of the CRASH-3 randomised trial
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Rashid Jooma6, Raoul Mansukhani1, Peter Sandercock7, Haleema Shakur-Still1, Temitayo Shokunbi8,9, Ian Roberts1
On behalf of the CRASH-3 trial collaborators

Abstract
Background: The CRASH-3 trial hypothesised that timely tranexamic acid (TXA) treatment might reduce deaths
from intracranial bleeding after traumatic brain injury (TBI). To explore the mechanism of action of TXA in TBI, we
examined the timing of its effect on death.
Methods: The CRASH-3 trial randomised 9202 patients within 3 h of injury with a GCS score ≤ 12 or intracranial
bleeding on CT scan and no significant extracranial bleeding to receive TXA or placebo. We conducted an
exploratory analysis of the effects of TXA on all-cause mortality within 24 h of injury and within 28 days, excluding
patients with a GCS score of 3 or bilateral unreactive pupils, stratified by severity and country income. We pool data
from the CRASH-2 and CRASH-3 trials in a one-step fixed effects individual patient data meta-analysis.
Results: There were 7637 patients for analysis after excluding patients with a GCS score of 3 or bilateral unreactive
pupils. Of 1112 deaths, 23.3% were within 24 h of injury (early deaths). The risk of early death was reduced with TXA
(112 (2.9%) TXA group vs 147 (3.9%) placebo group; risk ratio [RR] RR 0.74, 95% CI 0.58–0.94). There was no
evidence of heterogeneity by severity (p = 0.64) or country income (p = 0.68). The risk of death beyond 24 h of
injury was similar in the TXA and placebo groups (432 (11.5%) TXA group vs 421 (11.7%) placebo group; RR 0.98,
95% CI 0.69–1.12). The risk of death at 28 days was 14.0% in the TXA group versus 15.1% in the placebo group (544
vs 568 events; RR 0.93, 95% CI 0.83–1.03). When the CRASH-2 and CRASH-3 trial data were pooled, TXA reduced
early death (RR 0.78, 95% CI 0.70–0.87) and death within 28 days (RR 0.88, 95% CI 0.82–0.94).
Conclusions: Tranexamic acid reduces early deaths in non-moribund TBI patients regardless of TBI severity or
country income. The effect of tranexamic acid in patients with isolated TBI is similar to that in polytrauma.
Treatment is safe and even severely injured patients appear to benefit when treated soon after injury.
Trial registration: ISRCTN15088122, registered on 19 July 2011; NCT01402882, registered on 26 July 2011.
Keywords: Traumatic brain injury, Tranexamic acid, CRASH-3 trial, Randomised controlled trial, Intracranial
haemorrhage, Epidemiology, Emergence care
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Background
The acute management of traumatic brain injury (TBI)
aims to avoid secondary brain damage and optimise conditions for recovery [1]. The day of the injury is the most
hazardous, accounting for one third of in-hospital deaths
[2]. Some TBI victims have brain damage that is incompatible with life and die shortly after admission. In many
patients, intracranial bleeding starts soon after impact
and continues for several hours, with the majority of
haematoma expansion occurring within 1–1.5 h of injury
[3, 4]. The accumulating blood can increase intracranial
pressure, causing cerebral herniation and death. Tranexamic acid reduces bleeding in surgery and reduces death
from bleeding in traumatic and post-partum haemorrhage [5–7]. The therapeutic premise of the CRASH-3
trial was that timely tranexamic acid treatment might
curtail intracranial bleeding and prevent some of the
early bleeding-related deaths. A 1-g bolus started within
3 h of injury was followed by an infusion of 1 g over 8 h.
Tranexamic acid has a half-life of 2 h and by the second
day is almost completely eliminated. By this time, the
bleeding will have stopped, but other pathological processes, likely unaffected by tranexamic acid, will continue to cause deaths. Those who survive the first day
run the risk of cerebral oedema, diffuse axonal injury,
organ failure, sepsis, pneumonia and many other threats,
some iatrogenic, that make up the remaining two thirds
of in-hospital deaths.
The management of TBI is only partly based on results
from randomised trials. In practice, doctors draw on
pathophysiological knowledge, the available evidence
and their clinical experience to identify mechanisms of
brain damage and target physiologically based treatment
accordingly [3]. Large randomised trials can reduce our
therapeutic uncertainty, but to categorise them as positive or negative based on arbitrary p value thresholds is
inappropriate [8–10]. The CRASH-3 trial results have
variously been described as ‘negative’, ‘neutral’ or ‘a win
for patients with head injury’ that will benefit patients
[11–13]. We argue that randomised trials can deepen
our understanding of pathophysiology and that mechanistic insights should inform their interpretation. To explore the mechanism of action of tranexamic acid in TBI
patients, we examined the timing of its effect on death.
We also set the results of our analysis in the context of
other trials of tranexamic acid in TBI and polytrauma
patients, taking into consideration current treatment
guidelines that exclude patients with isolated TBI.
Methods
The background to the CRASH-3 trial, the methods,
baseline characteristics and main results were previously
reported [2, 6, 14]. Briefly, adults with TBI who were
within 3 h of injury and had a Glasgow coma scale score
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(GCS) ≤ 12 or any intracranial bleeding on CT scan and
no significant extra-cranial bleeding were eligible. The
time window for eligibility was originally 8 h, but in
2016, the protocol was changed to limit recruitment to
within 3 h of injury. Between July 2012 and January
2019, we randomly allocated 12,737 patients with TBI to
receive tranexamic acid or placebo, of whom 9202 patients were treated within 3 h. Patients were assigned by
selecting a numbered treatment pack from a box containing eight packs that were identical apart from the
pack number. Patients, care givers and those assessing
outcomes were masked to treatment allocation.
Based on previous research on the mechanism of tranexamic acid in bleeding trauma patients, we hypothesised that tranexamic acid would have a greater effect on
deaths soon after injury, since early bleeding-related
deaths have the most potential to be reduced by tranexamic acid [15]. We pre-specified this hypothesis in the
statistical analysis plan that we published before unblinding [14]. We also anticipated that the treatment effect would be diluted by the inclusion of patients with a
GCS score of 3 or unreactive pupils who have a very
poor prognosis regardless of treatment [14]. The trial results were consistent with both of these hypotheses [2].
The pre-specified primary outcome in the CRASH-3
trial was death due to head injury within 28 days among
patients treated within 3 h of injury. Although our scientific reasons for pre-specifying head injury death as the
primary outcome were given in the statistical analysis
plan and presented in detail elsewhere [16], there has
been strong interest in the effects of tranexamic acid on
all-cause mortality. As such, this analysis focusses on
early deaths from any cause, excluding patients with a
GCS score of 3 or bilateral unreactive pupils. Analyses
of head injury deaths and analyses including patients
with a GCS score of 3 or bilateral unreactive pupils are
presented in the Additional file 1 for comparison with
the results presented below and for cross-reference with
the main trial results.
We examine the temporal distribution of deaths from
any cause in the CRASH-3 trial. We explore the effects
of tranexamic acid on deaths due to any cause within 24
h of injury and on deaths due to any cause within 28
days, stratified by severity and country income level. We
use the baseline GCS score to define severity—mild to
moderate (GCS 9–15) and severe (GCS 3–8)—and
World Bank definitions to determine country income
level (LMIC vs HIC). Because a subgroup analysis demonstrated effect modification by severity, we explore this
further. Because most patients were from LMICs, the
generalisability of the results to HICs has been questioned and so we explore how the treatment effects vary
by country income level. To check if the effect on early
deaths could be explained by undiagnosed extra-cranial
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bleeding, we conducted a sensitivity analysis excluding
patients with hypotension (SBP < 90 mmHg). We also
examined the effects of tranexamic acid on vascular occlusive events (fatal and non-fatal) in all patients irrespective of time to treatment because theoretically the
potential risk of vascular occlusive events would be
greater with late treatment as there is a shift from a fibrinolytic to a coagulopathic state. We report risk ratios,
95% confidence intervals and heterogeneity p values. We
excluded 98 patients with missing outcome data.
We prespecified an analysis setting the results of the
CRASH-3 trial in the context of other evidence, including the CRASH-2 trial, in which 40% of deaths were due
to head injury [14]. The CRASH-3 trial essentially represents a subgroup of patients with isolated TBI who were
excluded from the CRASH-2 trial. Here, to set our results in the context of tranexamic acid in polytrauma patients, we pooled the data from the CRASH-2 and CRAS
H-3 trials in a one-step fixed effects individual patient
data meta-analysis using a Poisson regression model
with sandwich variance estimation, adjusted for time to
treatment. In the main CRASH-3 trial publication, we
updated a systematic search for randomised trials of
tranexamic acid in TBI. We searched PubMed, Science
Citation Index, National Research Register, Zetoc,
SIGLE, Global Health, LILACS, Current Controlled Trials, the Cochrane Injuries Group Specialised Register,
CENTRAL, MEDLINE and EMBASE. We identified
three trials in addition to the CRASH-3 trial including
the CRASH-2 intracranial bleeding study, a randomised
trial of 283 TBI patients sponsored by Khon Kaen University [17] and a randomised trial of pre-hospital tranexamic acid in 967 TBI patients sponsored by the
University of Washington (NCT01990768). The CRAS
H-2 intracranial bleeding study was omitted as this is
already contained within the CRASH-2 trial dataset, and
the small Thai study was omitted due to a lack of data
on timing of death, cause of death and GCS score, and
limitations in methodological quality including an unclear risk of selection bias from allocation concealment.
The model for the one-step meta-analysis was as
follows:
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excluding patients with a GCS score of 3 or bilateral unreactive pupils, and on vascular occlusive events in all
patients. An aggregate data meta-analysis was used because we did not have access to the individual patient
data for trial NCT01990768.

Results
Among the 12,639 randomised patients with outcome
data available, 9127 were treated within 3 h of injury. A
total of 1490 patients had GCS score of 3 or bilateral unreactive pupils at baseline (16.3%), leaving 7637 patients
for analysis. There were 1112 deaths from all causes
within 28 days, of which 259 (23.3%) occurred within 24
h of injury (early deaths) and 853 (76.7%) were beyond
24 h of injury. Figure 1 shows the time interval from injury to death in placebo-treated patients overall and according to severity and country income. Overall, the
proportion of early deaths was larger in severe head injury (28.1%) and in LMICs (24.1%).
Effect of tranexamic acid on early deaths

The risk of early death was lower in patients with mildto-moderate head injury compared to severe head injury
(1.1% vs 9.9%) and in HICs compared to LMICs (2.0% vs
3.8%). The risk of early death was reduced with tranexamic acid (112 (2.9%) deaths in the tranexamic acid
group vs 147 (3.9%) deaths in the placebo group; risk ratio [RR] RR 0.74, 95% CI 0.58–0.94; see Table 1). There
was no evidence that the effect of tranexamic acid on
early deaths varied by severity (heterogeneity p = 0.64)
or by country income (heterogeneity p = 0.68). When
114 (1.5%) patients with hypotension (SBP < 90 mmHg)
at baseline were excluded from the analyses, the results
were essentially the same (106 (2.8%) deaths in the tranexamic acid group vs 143 (3.9%) deaths in the placebo
group; RR 0.72, 95% CI 0.56–0.92). The effect of tranexamic acid on early death was smaller (261 vs 315 events;
RR 0.81, 95% CI 0.69–0.95) when we included patients
who had a GCS score of 3 or bilateral unreactive pupils
at baseline (see Appendix Table 1). The effect was larger
when the analysis was restricted to head injury-related
deaths only (Appendix Tables 2 and 3).

log π ¼ β0 þ β1 trial þ β2 group þ β3 ttt
Effect of tranexamic acid on deaths after 24 h

where trial = 0 for CRASH-2 and 1 for CRASH-3,
group = 0 for placebo and 1 for TXA, ttt is time to treatment and β2 is the summary effect estimate across both
trials.
We also consider the CRASH-3 trial results in the
context of the CRASH-2 trial and the trial of prehospital tranexamic acid (NCT01990768) using an aggregate data meta-analysis with fixed effects to assess
the effect of tranexamic acid on death at 28 days

The risk of death more than 24 h after injury was lower
in patients with mild-to-moderate head injury compared
to severe head injury (6.3% vs 25.2%) and in HICs compared to LMICs (8.2% vs 12.1%). The risk of death from
all causes beyond 24 h of injury was similar in the tranexamic acid and placebo groups (432 (11.5%) deaths in
the tranexamic acid group vs 421 (11.7%) deaths in the
placebo group; RR 0.98, 95% CI 0.69–1.12; see Table 1).
The effect on deaths beyond 24 h was similar by severity
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Fig. 1 Days from injury to death in placebo group patients randomised within 3 h of injury overall and by severity (GCS) and country income,
excluding those with GCS 3 or bilateral unreactive pupils

(heterogeneity p = 0.088) and country income (heterogeneity p = 0.36).

severity (heterogeneity p = 0.11) and country income
(heterogeneity p = 0.35).

Effect of tranexamic acid on deaths at 28 days

The risk of death at 28 days was lower in mild-tomoderate head injury compared to severe head injury
(7.4% vs 35.1%) and in HICs compared to LMICs
(10.1% vs 15.9%). The risk of death from any cause at
28 days was 14.0% in the tranexamic acid group versus
15.1% in the placebo group (544 vs 568 events; RR 0.93,
95% CI 0.83–1.03; see Table 1). The effect of tranexamic
acid on all-cause mortality at 28 days was similar by

Effect of tranexamic acid on vascular occlusive events

Among the 12,639 randomised patients with outcome
data, there were 203 (1.6%) fatal or non-fatal vascular
occlusive events. The absolute risk of vascular occlusive
events in all patients was lower in mild-to-moderate
head injury than in severe head injury (1.2% vs 2.4%)
and in LMICs compared to HICs (1.0% vs 3.0%). The
risk of vascular occlusive events was 1.6% in both the
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Table 1 Effect of early tranexamic acid on all-cause mortality within 24 h of injury, after 24 h and at 28 days stratified by severity and
country income level in patients randomised within 3 h of injury, excluding those with a GCS score of 3 or bilateral unreactive pupils
Within 24 h

After 24 h

TXA

Placebo

n (%)

n (%)

TXA

Placebo

n (%)

n (%)

112 (2.9)

147 (3.9)

0.74 (0.58–0.94)

432 (11.5)

421 (11.7)

Mild/moderate

25 (0.9)

37 (1.3)

0.66 (0.40–1.09)

163 (5.8)

Severe

87 (8.5)

110 (11.3)

0.75 (0.58–0.98)

LMIC

98 (3.3)

126 (4.4)

HIC

14 (1.5)

21 (2.4)

All patients

RR (95% CI)

At 28 days
RR (95% CI)

TXA

Placebo

n (%)

n (%)

RR (95% CI)

0.98 (0.69–1.12)

544 (14.0)

568 (15.1)

0.93 (0.83–1.03)

186 (6.9)

0.85 (0.69–1.04)

188 (6.7)

223 (8.1)

0.82 (0.68–0.99)

269 (28.7)

235 (27.2)

1.05 (0.91–1.22)

356 (34.7)

345 (35.4)

0.98 (0.87–1.10)

0.75 (0.58–0.98)

363 (12.6)

344 (12.5)

1.01 (0.88–1.16)

461 (15.5)

470 (16.3)

0.95 (0.84–1.07)

0.65 (0.33–1.26)

69 (7.7)

77 (9.0)

0.86 (0.63–1.18)

83 (9.2)

98 (11.1)

0.82 (0.62–1.08)

Severity

Country income

tranexamic acid and placebo groups (101 vs 102 events;
RR 0.98, 95% CI 0.74–1.28; see Table 2).

The results of the CRASH-3 trial in context

When the CRASH-2 and CRASH-3 trial data were
pooled in a one-stage individual patient data metaanalysis, early tranexamic acid reduced death within 24 h
of injury (RR 0.78, 95% CI 0.70–0.87) and death within
28 days (RR 0.88, 95% CI 0.82–0.94), with no evidence of
heterogeneity by trial (death within 24 h p = 0.60; death
within 28 days p = 0.18; see Fig. 2). Adjusting for time to
treatment made no difference to the results. For deaths
with 24 h of injury, the adjusted RR = 0.78 (95% CI 0.70–
0.87), and for death within 28 days the adjusted RR =
0.88 (95% CI 0.82–0.94). When a US trial of pre-hospital
tranexamic acid for isolated TBI was included in an aggregate data meta-analysis on death from any cause at
28 days, the results were identical (RR 0.88, 95% CI
0.82–0.94), with no evidence of heterogeneity by trial
(p = 0.41). There was no difference in the risk of vascular
occlusive events between treatment groups (RR 0.87,
95% CI 0.74–1.02), again with no heterogeneity by trial
(p = 0.42).
Table 2 Effect of tranexamic acid on vascular occlusive events
(fatal and non-fatal) at 28 days in all patients, stratified by
severity and country income level
TXA
N
All patients

Placebo
n

(%)

N

n

RR (95% CI)
(%)

6359 101 (1.6) 6280 102 (1.6) 0.98 (0.74–1.28)

Severity
Mild/moderate 4066 41

(1.0) 3997 52

(1.3) 0.76 (0.52–1.16)

Severe

2264 60

(2.7) 2247 50

(2.2) 1.19 (0.82–1.73)

LMIC

4375 50

(1.1) 4330 35

(0.8) 1.41 (0.92–2.17)

HIC

1984 51

(2.6) 1950 67

(3.4) 0.75 (0.52–1.07)

Country income

Discussion
Based upon this post hoc, exploratory analysis of the
CRASH-3 trial, tranexamic acid reduces deaths on the
day of the injury regardless of TBI severity and country
income but has no apparent effect on deaths beyond the
day of the injury. The effect of tranexamic acid on allcause mortality at 28 days is a weighted average of these
early and late effects and, although diluted toward the
null, is similar to the results of the CRASH-2 trial and
indicative of a survival benefit.
Because a larger proportion of deaths in the CRASH-3
trial occurred after 24 h (69% in CRASH-3 versus 43% in
CRASH-2), the effect on mortality at 28 days is smaller
(more diluted) in the CRASH-3 trial, although there is
no evidence of heterogeneity. As anticipated in the statistical analysis plan, the effect is smaller when including
patients with un-survivable injuries prior to treatment.
Tranexamic acid did not increase the risk of adverse vascular occlusive events in trauma patients.
Because our choice of head injury death as the primary
outcome measure was criticised, these analyses report
all-cause mortality. The trial inclusion criteria were clinical and reflect the situation that doctors face in practice.
We enrolled TBI patients within 3 h of injury if they had
no significant extra-cranial bleeding. The effect of tranexamic acid on early deaths is not explained by undiagnosed extra-cranial bleeding. Only 1.5% of patients had
hypotension (SBP < 90 mmHg) at baseline and only 11 of
the 1112 deaths (six in the tranexamic acid group and
five in the placebo group) were classified as extracranial
bleeding deaths. When patients with hypotension are excluded, the results are the same. The reduction in allcause mortality within 24 h strongly suggests that tranexamic acid reduces intracranial bleeding deaths.
We conducted the CRASH-3 trial because there was
reason to believe that tranexamic acid could reduce
bleeding-related head injury deaths. Increased fibrinolysis is common in TBI patients and worsens intracranial
bleeding. The CRASH-2 trial in 20,211 polytrauma
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Fig. 2 Evidence on the effect of early tranexamic acid on all-cause mortality within 24 h and 28 days of injury, excluding patients with a GCS
score of 3 or bilateral unreactive pupils at baseline

patients (extra-cranial and intra-cranial injury) with
significant bleeding found that tranexamic acid reduces mortality, primarily by reducing bleeding deaths
on the day of the injury [15]. Because the CRASH-2
trial was large, this early benefit was still apparent at
28 days, although ‘diluted’ by non-bleeding deaths.
The CRASH-3 trial was smaller than the CRASH-2
trial, and so despite the higher mortality rate, there
were fewer deaths and less statistical power to detect
the diluted effect on all-cause mortality at 28 days. A
non-significant difference between two groups in a
randomised trial can be real difference that is not significant due to a lack of power, or it can be a difference that has occurred by chance. In this case (Table
1), there is a large reduction in deaths within 24 h
with tranexamic acid (RR = 0.74) that is highly statistically significant and consistent with the expected biological effects of tranexamic acid but no apparent
reduction in deaths beyond 24 h (RR = 0.98). Because

the relative risk at 28 days is a weighted average of
these effects, the modest reduction in death at 28 days
(RR = 0.93) is not statistically significant. We believe
the reduction in deaths at 28 days is a real reduction
that is not significant due to a lack of statistical
power. This interpretation is consistent with biology
(intracranial bleeding occurs early, and there is little
or no tranexamic acid in the body beyond 24 h) and
as shown in the next paragraph is mathematically
consistent with dilution. The reduction in deaths at
28 days in the CRASH-3 trial is similar to that seen
in the larger (and more powerful) CRASH-2 trial, and
when the results are pooled, the reduction in deaths
at 28 days with tranexamic acid is highly significant.
However, we accept that can never rule out chance as
a potential explanation.
Because ‘dilution’ is key to understanding the
CRASH-3 results, it is best considered quantitatively.
Figure 3 shows results from a hypothetical trial in

Fig. 3 Hypothetical trial in which the effect on all-cause mortality is a weighted average of the effect on cause-specific mortality. The trial
treatment reduces the risk of early (bleeding) deaths by one quarter (RR = 0.75) but has no effect on late (non-bleeding) deaths (RR = 1.00). The
overall relative risk for all-cause mortality at the end of follow-up is a weighted average of these relative risks (RR = 0.92)
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which the treatment reduces the risk of early bleeding deaths (red circles) by one quarter (relative risk =
0.75), but has no effect (relative risk = 1.00) on later
non-bleeding deaths (blue circles). The relative risk
at the end of the follow-up period is a weighted
average of these relative risks: relative risk = 0.75(4/
12) + 1.0(8/12) = 11/12 = 0.92, where (4/12) and (8/12)
are the proportions of deaths in the untreated group
that are early or late. Because the relative risk at the
end of follow-up is closer to the null (0.92 versus
0.75), and smaller effects are harder to detect, the
treatment effect is less visible and, in this sense, is
diluted. But the biological effect did not change. It
was not offset by any harm but was simply obscured
by deaths unrelated to its mechanism of action.
Deaths that are inevitable before randomisation also
dilute treatment effects. Many patients with a GCS
score of 3 or unreactive pupils have un-survivable
injuries and will die soon after admission regardless
of treatment. Errors in the estimation of the time of
injury could result in the inclusion of patients outside the eligibility time window, and because late
treatment is less effective, this will also cause dilution. This is most relevant in LMICs where patients
are often taken to hospital by bystanders or family
members in private vehicles with no recording of the
time of injury.
Because no treatment has effects on all causes of
death, all-cause mortality at 28 days is a composite outcome that combines deaths affected by the trial treatment with those that are unaffected by it [16]. Using allcause mortality to assess the ‘true’ effect of a treatment
has counterintuitive consequences since it means that
the effect of any given treatment depends on the effects
of all the others. An antibiotic that reduces pneumonia
deaths in week 2, by reducing the proportion of late
deaths, will appear to increase the effectiveness of a
treatment for early bleeding. Because the proportion of
late deaths varies with injury severity and in different locations, all-cause mortality is not generalisable. The only
generalisable measure is the undiluted biological effect
of the trial treatment.

Conclusions
Tranexamic acid safely reduces early deaths in nonmoribund TBI patients regardless of TBI severity or
country income. The effect of tranexamic acid in patients with isolated TBI is similar to that in polytrauma,
reducing deaths on the day of the injury by over 20% in
the CRASH-2 and the CRASH-3 trials. Tranexamic acid
is included in treatment guidelines for the pre-hospital
care of bleeding trauma patients, but patients with isolated TBI were excluded. The CRASH-3 trial data support the reconsideration of tranexamic acid for
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administration in isolated TBI, and even severely injured
patients appear to benefit when treated soon after injury.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13054-020-03243-4.
Additional file 1: Supplementary Table 1. Effect of tranexamic acid
on all-cause mortality within 24 hours of injury, after 24 hours and at 28
days stratified by severity and country income in patients randomised
within 3 hours of injury. Supplementary Table 2. Effect of tranexamic
acid on head injury death within 24 hours, after 24 hours and at 28 days
by severity and country income in patients randomised within 3 hours of
injury, excluding those with GCS 3 or bilateral unreactive pupils.
Supplementary Table 3. Effect of tranexamic acid on head injury death
within 24 hours, after 24 hours and at 28 days by severity and country
income in patients randomised within 3 hours of injury.
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Shakur-Still. Data Monitoring and Ethics Committee—Michael J Clarke (chair),
Samuel C Ohaegbulam, Anthony Rodgers, and Tony Brady (independent
statistician). Protocol Committee—Ian Roberts, Haleema Shakur-Still, Yashbir
Dewan, Phil Edwards, Edward O Komolafe, Jorge Mejia-Mantilla, and Pablo
Perel. Clinical Trials Unit (CTU)—Monica Arribas (trial manager and research
assistant), Emma Austin (assistant trial manager), Eni Balogun (trial manager),
Lin Barneston (data manager 2011–2012), Collette Barrow (trial administrator),
Danielle Beaumont (senior trial manager and research fellow), Myriam Benyahia (CTU administrator), Amy Brenner (research fellow), Imogen Brooks (trial
assistant 2016–2018), Madeleine Cargill (data assistant), Laura Carrington (assistant trial administrator), Lisa Cook (assistant trial manager 2011), Beatrice
Cornu-Hewitt (trial assistant), Phil Edwards (statistician 2011–2016), Lauren
Frimley (trial manager and research assistant), Amber Geer (assistant data
manager), Daniel Gilbert (data assistant 2012–2013), Catherine Gilliam (trial
administrator), Julio Gil-Onandia (trial assistant), Daniel Hetherington (trial assistant 2012–2013), Courtenay Howe (CTU administrator 2015–2017), Carolyn
Hughes (data assistant 2016–2017), David I’anson (assistant trial manager
2016–2017), Rob Jackson (data manager 2012–2014), Miland Joshi (statistician
2016–2017), Sneha Kansagra (assistant trial manager 2016–2018), Taemi
Kawahara (senior trial manager 2011–2015), Katharine Ker (lecturer), Sergey
Kostrov (systems officer), Abda Mahmood (PhD candidate), Raoul Mansukhani
(medical statistician), Hakim Miah (IT systems manager), Bernard Ndungu (assistant trial manager 2016–2017), Kelly Needham (medical statistician), Cecilia
Okusi (data assistant 2014), Aroudra Outtandy (trial assistant 2013–2015), Raul
Pardinaz-Solis (assistant trial manager 2012–2013), Daniel Pearson (data assistant), Tracey Pepple (acting senior data manager), Claude Pisani (assistant trial
manager 2013), Jason Pott (lead UK research nurse 2018), David PrietoMerino (statistician 2012–2015), Danielle Prowse (assistant data manager),
Nigel Quashi (data manager 2013–2016), Anna Quinn (data assistant 2013–
2015), Maria Ramos (senior project administrator 2011–2015), Mia Reid (clerical assistant 2016–2018), Ian Roberts (chief investigator and CTU co-director),
Chris Roukas (trial administrator 2013–2015), Giulia Scrapa (assistant trial manager 2018), Haleema Shakur-Still (project director and CTU co-director), Chelci
Squires (trial assistant 2014–2016), Jemma Tanner (clinical trials associate
2013–2016), Andrew Thayne (data assistant), Lesley Vidaurre (assistant trial
manager 2012), and Elizabeth Woods (assistant trial manager 2012–2015).
Nigeria Coordinating Team—Bukola Fawole (coordinating centre director),
Olusade Adetayo (assistant trial coordinator), Olujide Okunade (assistant trial
coordinator), and Temitayo Shokunbi (clinical lead). Pakistan Coordinating
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Team—Rizwana Chaudhri (coordinating centre director), Kiran Javaid (assistant research coordinator), Rashid Jooma (clinical lead), and Aasia Kayani (research coordinator). National Coordinators—Rizwana Chaudhri (Pakistan),
Rashid Jooma (Pakistan), Sabariah Faizah Bt Jamaluddin (Malaysia), Julina Md
Noor (national coordinators assistant, Malaysia), Tamar Gogichaishvili
(Georgia), Maria de los Angeles Munoz-Sanchez (Spain), Bukola Fawole
(Nigeria), Temitayo Shokunbi (Nigeria), Jorge Mejia-Mantilla (Colombia), Liliana Vallecilla (Colombia), Fatos Olldashi (Albania), Satish Krishnan (United
Arab Emirates), Vincent Djientcheu (Cameroon), Jorge Loria Castellanos
(Mexico), Frank Rasulo (Italy), Qadamkhear Hama (Iraq), Yakub Mulla (Zambia),
Prof Ioan Stefan Florian (Romania), Juan Tobar (El Salvador), Hussein Khamis
(Egypt), Conor Deasy (Ireland), Bobby Wellsh (Papua New Guinea), Jean
Williams-Johnson (Jamaica), Susilo Chandra (Indonesia), and Vincent Mutiso
(Kenya).
CRASH trial sites and investigators (number of patients randomly
assigned)
Pakistan (4567)—Lahore General Hospital Neurosurgery Unit I (1178): Rizwan
Butt, Muhammad Hammad Nasir, Salman Ahmad, Farwah Aslam, Khurram
Ishaque, Faheem Usmani, Shahrukh Rizvi, Farhad Ali, Omair Sajjad, and Ali
Zunair; Jinnah Postgraduate Medical Centre (700): Lal Rehman, Raza Rizvi,
Farrukh Javeed, Shakeel Ahmed, Asad Abbas, Ali Afzal, and Ali Mikdad;
Lahore General Hospital Neurosurgery Unit III (648): Asif Bashir, Anwar
Chaudary, Tariq Salahuddin, Bashir Ahemed, Shahrukh Rizvi, Faheem Usmani,
and Amir Aziz; Jinnah Hospital Lahore (619): Naveed Ashraf, Shahzad Hussain,
Usman Ahmad, Muhammad Asif, Muhammad Adil, and Adeel Rauf; Lahore
General Hospital Neurosurgery Unit II (607): Khalid Mahmood, Rizwan Khan,
Bilal Ahmad, Umair Afzal, Hassan Raza, and Quratul Ain; DHQ Hospital
Narowal (303): Sajjad Yaqoob, Qaiser Waseem, Muffasser Nishat, Suneel
Semvel, and Javed Iqbal; Services Hospital Lahore (226) Samra Majeed, Sana
Zulfiqar, Madeeha Iqbal, Nazia Majeed, and Manzoor Ahmed; DHQ
Rawalpindi (137): Nadeem Akhtar, Mohammad Malik, Yasir Shehzad, and
Muhammad Yousaf; DHQ Hospital Khuzdar (65): Abdul Wahid, Abdul Samad,
and Saifullah Shah; Lady Reading Hospital (31): Mumtaz Ali and Jehan Zeb;
Shifa International Hospital (29): Abdus Salam Khan and Adeela Irfan; Liaquat
National Hospital and Medical College (14): Salman Sharif; Liaquat University
Hospital (7): Riaz Memon; Aga Khan University Hospital (3): Rashid Jooma. UK
(3143)—Royal London Hospital (501): Ben Bloom, Tim Harris, Jason Pott,
Imogen Skene, Geoffrey Bellhouse, and Olivia Boulton; University Hospital
Coventry (312): Caroline Leech, Geraldine Ward, Catherine Jarvis, Carly
Swann, and Sathananathan Ratnam; Queen Elizabeth Hospital Birmingham
(302): Antonio Belli, Ronald Carrera, Kamal Yakoub, David Davies, and Emma
Fellows; St George’s Hospital (280): Phil Moss, Heather Jarman, Sarah
Rounding, Elizabeth Johnson, and Catherine Loughran; Salford Royal Hospital
(176): Fiona Lecky, Kate Clayton, Angiy Michael, and Angela Coumbarides;
Southmead Hospital (156): Jason Kendall, Beverley Faulkner, Ruth Worner,
and Emma Gendall; King’s College Hospital (155): Philip Hopkins, Paul Riozzi,
Hannah Cotton, and Raine Astin-Chamberlain; St Mary’s Hospital, London
(117): Mark Wilson, Jan Bodnar, Rachel Williams, and Alberto Rigoni; Aintree
University Hospital (108): Abdo Sattout, John Fletcher, Calum Edge, and Nina
Maryanji; Addenbrooke’s Hospital (103): Adrian Boyle, Susie Hardwick, Ellen
Nichols, and Catherine Hayhurst; Queen’s Medical Centre (100): Frank Coffey,
Chris Gough, Philip Miller, and Lucy Ryan; John Radcliffe Hospital (76): Melanie Darwent, Alexis Espinosa, and Sally Beer; Royal Stoke University Hospital
(71): Julie Norton, Holly Maguire, and Kay Finney; Derriford Hospital (67): Anthony Kehoe, Rosalyn Squire, and Alison Jeffery; Queen Alexandra Hospital
(60): Christiane Vorwerk, Denise Foord, and Eliot Wilkinson; Northern General
Hospital (57): Avril Kuhrt, Shammi Ramlakhan, and Stuart Reid; Royal Preston
Hospital (41): Andy Curran and Sean McMullan; Leeds General Infirmary (39):
Tajek Hassan and Stuart Nuttall; Great Western Hospital (32): Stephen Haig
and Saif Al-Nahhas; Southampton General Hospital (31): Diederik Bulters and
Ardalan Zolnourian; Dorset County Hospital (27): Tamsin Ribbons and Ian
Mew; Gloucestershire Royal Hospital (27): Tanya de Weymarn and Victoria
Hughes; Royal Liverpool Hospital (21): Jane McVicar; Queen Elizabeth University Hospital (20): Cieran McKiernan; Royal Berkshire Hospital (20): Liza Keating; Poole Hospital (17): Henrik Reschreiter; James Cook University Hospital
(16): Judith Wright; Basingstoke and North Hampshire Hospital (13): Louisa
Chan; Whiston Hospital (13): Himanshu Kataria; Glasgow Royal Infirmary (12):
Alastair Ireland; Manchester Royal Infirmary (12): Richard Body; Royal Alexandra Hospital (12): Alasdair Corfield; Milton Keynes University Hospital (11):
Shindo Francis; Hull Royal Infirmary (10): William Townend; Leicester Royal Infirmary (10): Timothy Coats; Musgrove Park Hospital (10): James Gagg;
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Wexham Park Hospital (10): Sarah Wilson; Royal Sussex County Hospital (8):
Rowley Cottingham; Blackpool Victoria Hospital (7): Simon Tucker; Norfolk
and Norwich University Hospital (7): Frank Sutherland; North Devon District
Hospital (7): Louisa Mitchell; Whipps Cross University Hospital (7): Tim Harris;
Whittington Hospital (7): Lucy Parker; Darlington Memorial Hospital (6): Ola
Afolabi; Monklands Hospital (6): Fiona Hunter; Royal Cornwall Hospital (6):
Mark Jadav; University Hospital of North Tees (6): Kayode Adeboye; Worthing
Hospital (5): Mandy Grocutt; Royal Oldham Hospital (4): Gabrielle May; Royal
United Hospitals Bath (4): David Watson; Arrowe Park Hospital (3): Andrea
Wootten; Pinderfields General Hospital (3): Sarah Robertshaw; Birmingham
Heartlands Hospital (2): Susan Dorrian; Gwynedd Hospital, Bangor (2): Rob
Perry; Newham University Hospital (2): Tim Harris; University Hospital Lewisham (2): Hyun Choi; Western Infirmary (2): Claire McGroarty; Worcestershire
Royal Hospital (1): Paul Shone; Yeovil District Hospital (1): David Maritz.
Malaysia (1567)—Hospital Sungai Buloh (410): Sabariah Jamaluddin, Julina
Noor, Norizan Rosli, Leonard Leong Sang Xian and Yong De Jun; Hospital
Sultanah Bahiyah (241): Fatahul Mohamed, Cheng Hee Song, Arman Hawari,
Leong Yuen Chin, and Hardawani Mohd Hussein; Hospital Sultanah Nur
Zahirah (205): Mohd Lotfi, Hafiq Hamid, Nujaimin Udin, Peck Lian, and See
Choo; Penang General Hospital (161): Kwanhathai Wong, Fathiyah Gani,
Mardhiah Jusoh, and Darrsini Rajakumar; Miri General Hospital (111): Chia
Boon Yang, Nur Shahidah Binti Dzulkiflee, Wong Chok Ky, and Muhaimin
Azwan Bin Mohd Azman; Hospital Raja Permaisuri Bainun (101): Adi Bin
Osman, Azma Haryaty Ahmad, Ramzuzaman Ismail, and Si Qi Lai; Hospital
Sultanah Aminah (94): Mohd Amin Bin Mohidin, Norwani Binti Deraman, and
Salliza Binti Selamat; Hospital Tuanku Fauziah (72): Ida Abidin, Nurkhairulnizam Halim, and Zuraini Bakar; Hospital Tengku Ampuan Afzan (41): Zainalabidin Mohamed Ismail, Badrul Hisham, and Ruhaida Kamal; Hospital Sultan
Abdul Halim (36): Zainal Effendy and Mashitah Ismail; Hospital Seberang Jaya
(30): Noor Azleen and Liu Yeo Seng; Universiti Sains Malaysia (26): Kamarul
Aryffin Baharuddin and Regunath Kandasamy; Hospital Langkawi (13): Azlan
Kamalludin; Hospital Kulim (8): Shamsul Asmee; Hospital Kemaman (7): Mohd
Fadzil; Hospital Segamat (6): Ahmad Basitz; Hospital Pakar Sultanah Fatimah
(5): Norhaya Abdullah. Georgia (771)— High Technology Medical Center, University Clinic (751): Tamar Gogichaishvili, Giorgi Ingorokva, Shota Ingorokva,
Iamze Agdgomelashvili, Kote Mumladze, Ioseb Maisuradze, and Iulia Kugusheva; Archangel St Michael Multiprofile Clinical Hospital (18): Buba Shalamberidze; City Hospital 1 (2): Gia Tomadze. Spain (425)—Hospital Regional
Universitario Carlos Haya (102): Juan Fernandez-Ortega, Raimundo SearaValero, Guillermo Ibañez-Botella, Victoria Garcia-Martinez; Hospital Alvaro
Cunqueiro VIGO (82): Melida Garcia Martul, Santiago Freita Ramos, Guillermo
Lago Preciado; Hospital Universitario Virgen del Rocio (77): Claudio GarciaAlfaro, Angeles Munoz-Sanchez, Rafael Bellido-Alba; Hospital General Universitario de Ciudad Real (67): Carmen Corcobado, Ana Bueno, Alfonso Ambros;
Complejo Hospitalario de Navarra (44): JuanTihista Jimenez, Jose Roldan
Ramirez; Hospital Torrecardenas (21): José Martín; Hospital de Lucus Augusti
(13): Laura Inés Rodríguez; Hospital Clinico de Barcelona (9): Jaime Fontanals;
Hospital Universitario Puerta del Mar de Cadiz (9): José Manuel Jiménez-Moragas; Hospital General Universitario De Albacete (1): Joaquín Paya Berbegal.
Nigeria (409)—National Hospital Abuja (64): Olaomi Oluwole, Raji Mahmud,
and Nancy Ukwu; Lagos University Teaching Hospital (55): Femi Bankole, Abidemi Oseni, and Bamidele Adebayo; University College Hospital, Ibadan (53):
Adefolarin Malomo, Liadi Tiamiyu, and Adefisayo Adekanmbi; Olabisi Onabanjo University Teaching Hospital (38): Lateef Thanni and Ayodeji Olubodun;
Federal Medical Centre Abeokuta (36): Fidelis Ojeblenu and Michael Uwaezuoke; Obafemi Awolowo University Teaching Hospitals (31): Edward Komolafe and Oluwafemi Owagbemi; Lagos State Accident and Emergency Centre
(22): Fatai Ishola; Bowen University Teaching Hospital Ogbomoso (17): Adewumi Durodola; Federal Medical Centre Lokoja (13): Ukpong Udoffa, Federal
Medical Centre Bida (12): Adeniran James; Abubakar Tafawa Balewa University Teaching Hospital (11): Azeez Tella; Irrua Specialist Teaching Hospital (9):
Andrew Dongo; Federal Medical Centre Umuahia (8): Uchechi Ekpemiro;
Nnamdi Azikiwe University Teaching Hospital (8): Stanley Anyanwu; State
Hospital, Ijaiye, Abeokuta (8): Nafiu Aigoro; University of Nigeria Teaching
Hospital Enugu (7): Wilfred Mezue; Jos University Teaching Hospital (6):
Danaan Shilong; University of Benin Teaching Hospital (6): Abiodun Azeez;
Federal Medical Centre Ido-Ekiti (2): Olakunle Babalola; Federal Teaching Hospital, Gombe (2): Mohammed Ibrahim; University of Abuja Teaching Hospital
(1): Joseph Obande. Colombia (335)—Hospital Pablo Tobon Uribe (127), Alfredo Constain Franco, Edwin Vasquez Salazar, Sebastian Betancur Londoño,
and Viviana Medina Cardona; Hospital Universitario San Vicente Fundacion
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(112): Carlos Morales; Santiago Upegui; Santiago Naranjo; July Agudelo; Fundacion Valle del Lili (96): Jorge Mejia-Mantilla, Sandra Carvajal, and Yidhira
Fajardo-Gaviria. Nepal (255)—Neuro Hospital (103): Yam Roka, Ushma Ghising,
Narayani Roka, and Manzil Shrestha; National Institute of Neurological and Allied Sciences (64): Upendra Devkota, Bivek Vaidya, and Pankaj Nepal;
Kathmandu Medical College Teaching Hospital (47): Amit Thapa and Bidur
KC; Chitwan Medical College Teaching Hospital (24): Ajit Shrestha; Bir Hospital
(11): Rajiv Jha; B & B Hospital Ltd. (6): Prabin Shrestha. Albania (214)—University Hospital of Trauma (214): Fatos Olldashi, Irgen Hodaj, Erion Spaho, Asllan
Selaj, and Nirian Bendo. Japan (165)—Matsudo City Hospital (64): Tomohisa
Shoko, Hideki Endo, and Atsushi Senda; Senshu Trauma and Critical Care
Centre (61): Yasushi Hagihara, Takashi Fuse, and Naohisa Masunaga; Tokyo
Medical and Dental University (28): Yasuhiro Otomo and Ryuichiro Egashira;
Teikyo University Hospital (12): Takahiro Ohnuki. United Arab Emirates
(126)—Al Qassimi Hospital (126): Satish Krishnan, Alya AlMazmi, Subrata Saha,
and Alexander Suvarov. Myanmar (121)—1000 Bedded Nay Pyi Taw Hospital
(121): Than Latt Aung, Kaung Myat Tun, Tint Tint Khaing, and Thinzar Maw.
Cameroon (116)—Yaounde Central Hospital (38): Vincent Djientcheu and
Orlane Ndome; Hopital General Douala (31): Mireille Moumi and André
Mbida; Hopital Laquintinie de Douala (28): Joseph Fondop and N’Diaye;
Yaounde General Hospital (19): Mba Sebastien. Afghanistan (87)—Nangarhar
University Teaching Hospital (87): Abdul Azim, Jan Adil, and Zabiullah Amiry.
Mexico (79)—Hospital Regional 25 IMSS (24): Jorge Loría-Castellanos; Hospital
General Jose G Parres (21): Nancy Guevara Rubio; Hospital General de Uruapan, Pedro Daniel Martinez (11): Patricia Ortega Leon; Hospital General Regional No 1 (10): Francisco Estrada; Hospital General de Zona 197 (8): Erandy
Montes de Oca-García; Hospital General Regional Bernardo Sepulveda (3):
Hafid Sanchez; Hospital General La Perla (2): Angélica Soria. Italy
(72)—Azienda Ospedaliera Universitaria Senese (35): Paola Bonucci and Federico Franchi; Fondazione Poliambulanza (19): Alan Girardini; Spedali Civili Di
Brescia (18): Frank Rasulo. Iraq (55)—Rozhawa Emergency Hospital (51):
Qadamkhear Hama, Himdad Hameed, and Muhammad Basim; Rojhelat Emergency Hospital (3): Qadamkhear Hama; Par Hospital (1): Qadamkhear Hama.
Cambodia (45)—World Mate Emergency Hospital (45): Simon Stock and Eap
Hourt. Zambia (44)—University Teaching Hospital Lusaka (40): Yakub Mulla
and Ali Ilunga; Kitwe Central Hospital (4): Jonathan Mulenga. Romania
(35)—Timisoara County Hospital (17): Horia Ples; Spitalul Sf Pantelimon
Bucharest (11): Adam Danil; Bagdasar-Arseni Emergency Clinical Hospital (5):
Mircea Gorgan; Cluj County Emergency Hospital (2): Ioan Florian. El Salvador
(28)—Hospital Nacional Rosales (28): Juan Tobar, Fernandez. Egypt
(20)—Mataria Teaching Hospital (20): Hussein Khamis. Slovenia (15)—University Medical Centre Ljubljana (15): Dusan Vlahovic. Ireland (12)—Cork University Hospital (12): Conor Deasy. Papua New Guinea (10)—Port Moresby
General Hospital (10): Bobby Wellsh. Canada (7)—Saint John Regional Hospital (7): James French. Jamaica (7)—Cornwall Regional Hospital (5): Jeffrey
East; University Hospital of the West Indies (2): Jean Williams-Johnson.
Indonesia (6)—Rumah Sakit Sekar Kamulyan (6): Antonius Kurniawan. Kenya
(1)—Kenyatta National Hospital, University of Nairobi (1): Julius Kiboi.
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